Prometheon's large animal pilot study of their needle-free insulin TruePatch™ has been completed and is expected to be included for publication in an international peer-reviewed diabetes journal before the end of Q4. Early results of testing completed in August 2016 had already confirmed that Prometheon's extended-wear basal insulin patch works to lower blood glucose levels in a type 1 diabetic mini-pig model. Dr. Stephen Hsu (CEO/CSO) designed the clinical trial to compare patch vs. subcutaneous needle injection delivery of the long-acting (basal) insulin analogue called glargine (LANTUS®, BASALIN®). Glargine for administration by injection will soon be available as a biosimilar from several other global generics manufacturers.Read More
Dr.Stephen Hsu (CEO/CSO) presented on Prometheon R&D team's history-making studies of an optimized TopiconENDO™ human growth hormone patch formulation for needle-free extended-wear hormone replacement therapy in children and adults. He delivered his oral presentation at Europe's most prestigious international gathering of pediatric endocrinologists and scientists--the 53rd Annual ESPE Meeting (Dublin, Ireland). He has been invited to serve as an abstract reviewer for the 54th Annual ESPE Meeting (Barcelona, Spain).